

REMARKS

Further to a March 20, 2009 interview initiated by the Examiner, summarized below, and solely to advance prosecution, claims 17-19 have been amended to incorporate the limitations of claims 21-23, respectively. Claims 21-23 have been canceled.

Further, claim 18 as amended also includes arthritis, cancer, irritable bowel syndrome and inflammatory lesions of joints, skin, muscles and nerves as recited indications. Support for the inclusion of these indications can be found, for example, on page 19 of the application as filed.


Claims 32-36 have been added. Claim 32 recites particular pain indications supported by claim 18 as originally filed and on page 19 of the application as-filed. Claims 33-36 depend from claims 32 and 17-19, respectively, and recite the particular compounds recited in claim 20 for administration in the methods claimed therein.

No new matter has been added by this amendment.

According to telephonic exchanges between the Examiner and the undersigned, claims 17-19 would be allowed by the Examiner if the limitations of claims 21-23 were incorporated therein. This amendment has been made in view of these discussions, and the limitations of claims 21-23 have been added to claims 17-19. As noted above, claim 18 also incorporates additional, specific indications set forth on page 19 of the applications as-filed; and claim 32 has been added to also recite specific indications.

Applicants request that the present application be passed to issuance.

Respectfully submitted,



Jason C. Chumney
Patent Registration No. 54,781

Attorney for Applicant
Telephone: 212-408-2500

Baker Botts L.L.P.
30 Rockefeller Center
New York, NY 10112

Date: May 15, 2009